ISH 2022 | Comparison of the safety & efficacy of CAR-T therapy vs bispecifics in R/R multiple myeloma
Borja Puertas-Martinez
• 8 Oct 2022
Borja Puertas, MD, University of Salamanca, Salamanca, Spain, describes the results of a study comparing the efficacy and safety of CAR-T therapy versus bispecific antibodies in patients with relapsed/refractory (R/R) multiple myeloma, commenting on differences in prior lines of therapy, time to access, and time to hospitalization as well as differences in overall response rates (ORR), complete response (CR) rate, and adverse events. This interview took place at the 38th World Congress of the International Society of Hematology 2022.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
